Lobbying Activity Report


Organization: Novartis Pharmaceuticals Canada Inc.
Associated registration: 1739-2301-25
Lobbying Activity date: 2021-07-02
Arranged a meeting: No
Posted date: 2021-07-13

In-house lobbyists who participated in the lobbying activity: Kimberly King Footnote1
Geoffrey Squires Footnote1
Senior Public Office Holders who were lobbied in this activity: Mitch Moneo, Assistant Deputy Minister
Pharmaceutical Laboratory & Blood Services, Health
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Requested a meeting with ADM Moneo to share details of the UK NHS program addressing Cardiovascular Disease (CVD) on a population wide basis as might be applied within a BC specific program should BC's Ministry of Health see value in adopting this approach.
In 2020 UK’s NHS (England) announced a program to identify patients at high-risk for CVD, and provide intensive treatment for these patients with the objectives of 1) reducing morbidity & mortality caused by CVD and 2) reducing overall costs associated with this disease. The NHS program is being implemented as a result of an innovative agreement between the NHS and Novartis Pharmaceuticals.
Background: According to the March 11th, 2021 Health Ministry report ‘Covid-19 in BC’ - Heart Disease is the second leading cause of death and the third leading cause of potential years of life lost in BC. Footnote1
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health, Hospitals Footnote1
Senior officer who filed this Lobbying Activity Report: Christian Macher
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
  1. Footnote1  Indicates new information that was added through a Lobbying Activity Report.

Date Modified: